- Home
- HMST vs ADAP Comparison
HMST vs ADAP Comparison
Compare HMST & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- ADAP
- Stock Information
- Founded
- HMST 1921
- ADAP 2008
- Country
- HMST United States
- ADAP United Kingdom
- Employees
- HMST N/A
- ADAP N/A
- Industry
- HMST Major Banks
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- ADAP Health Care
- Exchange
- HMST Nasdaq
- ADAP Nasdaq
- Market Cap
- HMST 191.6M
- ADAP 158.6M
- IPO Year
- HMST 2012
- ADAP 2015
- Fundamental
- Price
- HMST $10.74
- ADAP $0.55
- Analyst Decision
- HMST Buy
- ADAP Strong Buy
- Analyst Count
- HMST 2
- ADAP 4
- Target Price
- HMST $14.75
- ADAP $2.79
- AVG Volume (30 Days)
- HMST 195.0K
- ADAP 2.2M
- Earning Date
- HMST 01-27-2025
- ADAP 03-05-2025
- Dividend Yield
- HMST N/A
- ADAP N/A
- EPS Growth
- HMST N/A
- ADAP N/A
- EPS
- HMST N/A
- ADAP N/A
- Revenue
- HMST $169,710,000.00
- ADAP $175,041,000.00
- Revenue This Year
- HMST N/A
- ADAP $204.91
- Revenue Next Year
- HMST $17.03
- ADAP N/A
- P/E Ratio
- HMST N/A
- ADAP N/A
- Revenue Growth
- HMST N/A
- ADAP 146.27
- 52 Week Low
- HMST $8.09
- ADAP $0.53
- 52 Week High
- HMST $16.10
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- HMST 48.97
- ADAP 38.69
- Support Level
- HMST $9.36
- ADAP $0.55
- Resistance Level
- HMST $11.34
- ADAP $0.65
- Average True Range (ATR)
- HMST 0.51
- ADAP 0.05
- MACD
- HMST 0.09
- ADAP -0.00
- Stochastic Oscillator
- HMST 54.18
- ADAP 18.89
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.